Related Experiment Videos
[Lithium and acute myeloid leukemia]
Insights
Lithium carbonate, used for manic-depressive psychosis, may be linked to acute myeloid leukemia. Further research is needed to understand this potential association and its implications for patient safety.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Lithium carbonate is a common mood stabilizer for bipolar disorder.
- The potential long-term effects of lithium therapy on hematopoiesis require investigation.
Observation:
- A case study identified acute myeloid leukemia in a 34-year-old male patient undergoing lithium carbonate treatment.
- Seven additional cases of myeloid leukemia following lithium therapy were identified in the literature.
Findings:
- Lithium therapy was associated with the development of acute or chronic myeloid leukemia.
- Lithium was observed to enhance granulopoiesis, a process involved in white blood cell production.
Implications:
- Lithium may play a role in initiating or promoting the development of leukemia.
- Clinical vigilance for hematological malignancies is warranted in patients on long-term lithium treatment.
Abstract:
The authors report a case of acute myeloid leukemia in a thirty-four-year-old man who had been under lithium carbonate for the last six months for manic-depressive psychosis. One year after treatment with cytosine-arabinoside, 6-thioguanine and daunorubicin, the patient is still in complete remission. In the medical literature we found seven additional reports of acute or chronic myeloid leukemia after lithium therapy. Lithium was found to enhance granulopoiesis. Our findings suggest that lithium may initiate or promote leukemia.